申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2019243528A1
公开(公告)日:2019-12-26
The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations.
本发明涉及O-GlcNAc水解酶(OGA)抑制剂。该发明还涉及包含这类化合物的药物组合物,制备这类化合物和组合物的方法,以及利用这类化合物和组合物预防和治疗抑制OGA有益的疾病的用途,例如tau病变,特别是阿尔茨海默病或进行性上行性麻痹; 以及伴有tau病理的神经退行性疾病,特别是由C90RF72突变引起的肌萎缩性侧索硬化或额颞叶痴呆。